Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice. 2017

Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
Neuroscience Research Unit, Centre de Recherche du CHU de Québec, CHUL, 2705 Laurier Boulevard, Quebec City, Qc G1V 4G2, Canada; Faculty of Pharmacy, Laval University, 1050, Avenue de la Médecine, Quebec City, Qc G1V 0A6, Canada.

Ethanolamine plasmalogens (PlsEtn) are a class of glycerophospholipids characterized by a vinyl-ether bond at the sn-1 position that play an important role in the structure and function of membranes. Previous reports have suggested a link between reduced blood and brain PlsEtn levels and Parkinson's disease (PD). We recently reported that the DHA containing plasmalogen precursor PPI-1011 protected striatal dopamine (DA) against MPTP toxicity in mice. In this paper, we further investigate the specificity requirements of the lipid side chains by testing the oleic acid-containing plasmalogen precursor PPI-1025. Male mice were treated for 10days with daily oral administration of PPI-1025 (10, 50 or 200mg/kg). On day 5 mice received MPTP and were sacrificed on Day 11. Treatment with PPI-1025 prevented MPTP-induced decrease of DA and serotonin, as well as their metabolites. In addition, PPI-1025 treatment prevented the MPTP-induced decrease of the striatal dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) specific binding. Significant positive correlations were measured between striatal DA concentrations and DAT or VMAT2 specific binding, as well as with serum plasmalogen concentrations. The neuroprotective effect of PPI-1025 displayed a bell-curve dose-dependency losing effect at the highest dose tested. The similar protective response of oleic and docosahexaenoic acid (DHA)-containing plasmalogen precursors suggests that the neuroprotection observed is not only due to DHA but to the oleic substituent and the plasmalogen backbone.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010955 Plasmalogens GLYCEROPHOSPHOLIPIDS in which one of the two acyl chains is attached to glycerol with an ether alkenyl linkage instead of an ester as with the other glycerophospholipids. Phosphatidal Compounds,Plasmalogen,Alkenyl Ether Phospholipids,Compounds, Phosphatidal,Ether Phospholipids, Alkenyl,Phospholipids, Alkenyl Ether
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine
D017072 Neostriatum The phylogenetically newer part of the CORPUS STRIATUM consisting of the CAUDATE NUCLEUS and PUTAMEN. It is often called simply the striatum.
D050483 Dopamine Plasma Membrane Transport Proteins Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of dopaminergic neurons. They remove DOPAMINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS and are the target of DOPAMINE UPTAKE INHIBITORS. Dopamine Plasma Membrane Transporter Proteins,Neurotransmitter Transport Proteins, Dopamine-Specific,Neurotransmitter Transporters, Dopamine-Specific,DAT Dopamine Transporter,DAT Dopamine Transporter Proteins,Dopamine Carriers,Dopamine Transporter,Dopamine Transporter Proteins,Dopamine Uptake Complex,SLC6A3 Protein,Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3 Protein,Carriers, Dopamine,Dopamine Transporter, DAT,Dopamine-Specific Neurotransmitter Transporters,Neurotransmitter Transport Proteins, Dopamine Specific,Neurotransmitter Transporters, Dopamine Specific,Protein, SLC6A3,Transporter Proteins, Dopamine,Transporter, DAT Dopamine,Transporter, Dopamine,Transporters, Dopamine-Specific Neurotransmitter

Related Publications

Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
June 1993, European journal of pharmacology,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
June 2000, Neurotoxicology,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
October 1997, Neuroscience letters,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
March 2009, Neuroreport,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
August 1986, Research communications in chemical pathology and pharmacology,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
August 1988, Clinical neuropharmacology,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
September 2004, Neurotoxicology,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
June 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
May 1993, Neurochemical research,
Edith Miville-Godbout, and Mélanie Bourque, and Marc Morissette, and Sara Al-Sweidi, and Tara Smith, and Dushmanthi Jayasinghe, and Shawn Ritchie, and Thérèse Di Paolo
April 2001, Journal of neurochemistry,
Copied contents to your clipboard!